{"id":59298,"date":"2024-05-01T19:03:37","date_gmt":"2024-05-01T17:03:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/"},"modified":"2024-05-01T19:03:37","modified_gmt":"2024-05-01T17:03:37","slug":"remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/","title":{"rendered":"Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market"},"content":{"rendered":"
\n

\nMerck Global Head of R&D and Chief Medical Officer Danny Bar Zohar joins Former Israeli Prime Minister Naftali Bennett on Board of Directors<\/i><\/p>\n

NEW YORK–(BUSINESS WIRE)–Remepy, a pioneer in \u201chybrid drugs,\u201d today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M. The round was led by NFX, joined by Vine Ventures, PsyMed Ventures, Supernode Ventures and Firstime Ventures, joining previous pre-seed lead investor TechAviv as well as Fresh.fund, Samsung Next, StageNext Fund and 97212 Ventures.<\/p>\n

\nRemepy\u2019s new hybrid drugs combine traditional drugs with its \u201cdigital molecules.\u201d Digital molecules are therapeutic interventions that trigger physiological effects (aka MOAs, Mechanisms of Action) through the brain. These physiological changes have been known to enhance the effectiveness of traditional drugs.<\/p>\n

\nThe digital molecules are designed for hybrid drug experiences. They are based on non-invasive cognitive, psychological, and behavioral interventions that follow principles of sensory integration, sensory substitution and sensory deprivation. The interventions trigger multiple unique mechanisms of actions, including: changes to brain connectivity in important brain areas; changes to immune system blood biomarkers, and important behavioral changes.<\/p>\n

\nRemepy has already demonstrated the effects of its digital molecule interventions in clinical trials using extensive fMRI imaging, blood and saliva samples analysis and standardized questionnaires. It is among the first in the world to show that its patent\u2013pending digital therapies can modulate blood biomarkers.<\/p>\n

\nMany diseases are better treated by combining drugs with non-pharmacological interventions. Remepy is making such combinations standardized, accessible and personalized at scale with the use of its digital molecules.<\/p>\n

\nRemepy is targeting neurodegenerative diseases, cancer, autoimmune diseases, and degenerative eye diseases. Remepy\u2019s innovative approach creates a new market for hybrid medications, and a whole new world of data and IP assets for pharmaceutical companies.<\/p>\n

\nDr. Danny Bar Zohar, Merck\u2019s Global head of R&D and Chief Medical Officer, who shares the company\u2019s vision for hybrid drugs states: \u201cAs a physician and drug developer, it is fascinating for me to see Remepy\u2019s clinical data, which shows how these unique non-invasive digital interventions can modulate the immune system, make significant changes to brain plasticity, and drive behavioral changes. Remepy\u2019s product has the potential to enhance immunotherapy for cancer, or improve existing drug therapy for neurodegenerative diseases such as Parkinson\u2019s Disease and MCI (Mild Cognitive Impairment). These proprietary digital-drug combinations could significantly improve patient outcomes and create tangible value for patients and healthcare systems.\u201d<\/p>\n

\nDr. Michal Tsur, Remepy Co-CEO: \u201cI am thrilled that Dr. Danny Bar Zohar has joined us as a board member. Many industries have transformed by adopting a hybrid product approach, integrating new technology with traditional products.\u201d Co-CEO Or Shoval added: “I am particularly excited about the prospects of improving Parkinson\u2019s Disease patients\u2019 lives with a hybrid PD drug that will better address cognitive, movement, speech, sleeping and psychological symptoms and has the potential of disease modification with changes to brain connectivity.\u201d<\/p>\n

\n“Remepy’s vision of enhancing drugs with digital companions is groundbreaking and their clinical proof that such enhancement is possible is incredibly exciting,\u201d adds Gigi Levy-Weiss, Managing Partner at NFX \u201cRemepy has an experienced team of entrepreneurs and world-class scientists that are defining a new category in pharma.”<\/p>\n

\nAbout Remepy:<\/p>\n

\nRemepy is pioneering Hybrid Drugs: traditional drugs combined with digital therapeutics that are personalized and enhance the effect of pharmaceutical treatments. Remepy has already proven in human studies the effect of its products, using extensive brain imaging, as well as blood and saliva samples, with promising results for Oncology, MCI, and Parkinson\u2019s Disease. Their approach offers an efficient method to create new proprietary pharma assets, unlocking an entire new market and world of data. The Remepy team includes top scientists, physicians, and technologists.<\/p>\n

Contacts<\/b> <\/p>\n

\nMichal Tsur
\n
Press@Remepy.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Merck Global Head of R&D and Chief Medical Officer Danny Bar Zohar joins Former Israeli Prime Minister Naftali Bennett on Board of Directors NEW YORK–(BUSINESS WIRE)–Remepy, a pioneer in \u201chybrid drugs,\u201d today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M. The round was led by … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59298","6":"format-standard","7":"category-industry"},"yoast_head":"\nRemepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Merck Global Head of R&D and Chief Medical Officer Danny Bar Zohar joins Former Israeli Prime Minister Naftali Bennett on Board of Directors NEW YORK–(BUSINESS WIRE)–Remepy, a pioneer in \u201chybrid drugs,\u201d today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M. The round was led by ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-01T17:03:37+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market\",\"datePublished\":\"2024-05-01T17:03:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\\\/\"},\"wordCount\":646,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\\\/\",\"name\":\"Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2024-05-01T17:03:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/","og_locale":"en_US","og_type":"article","og_title":"Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market - Pharma Trend","og_description":"Merck Global Head of R&D and Chief Medical Officer Danny Bar Zohar joins Former Israeli Prime Minister Naftali Bennett on Board of Directors NEW YORK–(BUSINESS WIRE)–Remepy, a pioneer in \u201chybrid drugs,\u201d today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M. The round was led by ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/","og_site_name":"Pharma Trend","article_published_time":"2024-05-01T17:03:37+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market","datePublished":"2024-05-01T17:03:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/"},"wordCount":646,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/","url":"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/","name":"Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2024-05-01T17:03:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/remepy-launches-with-15-million-in-funding-to-bring-first-hybrid-drug-to-market\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59298"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59298\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}